Cargando…

MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy

Although resistance is its major obstacle in cancer therapy, trastuzumab is the most successful agent in treating epidermal growth factor receptor 2 positive (HER2 +) breast cancer (BC). Some patients show resistance to trastuzumab, and scientists want to circumvent this problem. This review elabora...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hosseinzadeh, Aysooda, Merikhian, Parnaz, Naseri, Nazanin, Eisavand, Mohammad Reza, Farahmand, Leila
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897942/ https://www.ncbi.nlm.nih.gov/pubmed/35248049 http://dx.doi.org/10.1186/s12935-022-02523-z

Ejemplares similares

Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling
por: Khodabakhsh, Farnaz, et al.
Publicado: (2021)

Triple-negative breast cancer: understanding Wnt signaling in drug resistance
por: Merikhian, Parnaz, et al.
Publicado: (2021)

Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk
por: Barzaman, Khadijeh, et al.
Publicado: (2022)

Recombinant nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and vascularization of spontaneous mouse mammary tumors
por: Merikhian, Parnaz, et al.
Publicado: (2021)

Comparison of mucin-1 in human breast cancer and canine mammary gland tumor: a review study
por: Vafaei, Rana, et al.
Publicado: (2022)

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
por: Peiró, G, et al.
Publicado: (2014)

TARGETING THE MUC1-C ONCOPROTEIN DOWNREGULATES HER2 ACTIVATION AND ABROGATES TRASTUZUMAB RESISTANCE IN BREAST CANCER CELLS
por: Raina, Deepak, et al.
Publicado: (2013)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression
por: Li, Guangchao, et al.
Publicado: (2014)

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
por: Luque-Cabal, María, et al.
Publicado: (2016)

Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance
por: Roukos, Dimitrios H.
Publicado: (2009)

β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
por: Park, Soeun, et al.
Publicado: (2022)

Flavonoids target different molecules of autophagic and metastatic pathways in cancer cells
por: Hosseinzadeh, Aysooda, et al.
Publicado: (2023)

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
por: Mitani, Seiichiro, et al.
Publicado: (2020)

Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance
por: Bailey, Tameka A., et al.
Publicado: (2011)

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
por: Upton, Rosalynd, et al.
Publicado: (2021)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer
por: Cufí, Sílvia, et al.
Publicado: (2013)

Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer
por: Nunes, Toni, et al.
Publicado: (2019)

Target Points in Trastuzumab Resistance
por: Shojaei, Sahar, et al.
Publicado: (2012)

Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer
por: Mercogliano, María F., et al.
Publicado: (2017)

Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
por: Lavaud, Pernelle, et al.
Publicado: (2014)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
por: Zhang, Mengqi, et al.
Publicado: (2022)

Identification of potential target genes of honokiol in overcoming breast cancer resistance to tamoxifen
por: Hermawan, Adam, et al.
Publicado: (2022)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Enhancement of extracellular bispecific anti‐MUC1 nanobody expression in E. coli BL21 (DE3) by optimization of temperature and carbon sources through an autoinduction condition
por: Rezaei, Leila, et al.
Publicado: (2020)

Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression
por: Bruni, Sofia, et al.
Publicado: (2023)

Resistance to Trastuzumab
por: Vivekanandhan, Sneha, et al.
Publicado: (2022)

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
por: Diessner, J, et al.
Publicado: (2014)

Identification of KLK10 as a therapeutic target to reverse trastuzumab resistance in breast cancer
por: Wang, Zhuo, et al.
Publicado: (2016)

N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by (89)Zr-Trastuzumab and (18)F-FDG PET imaging
por: Wimana, Zéna, et al.
Publicado: (2017)

Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
por: Vu, Thuy, et al.
Publicado: (2012)

Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance
por: Palomeras, Sònia, et al.
Publicado: (2018)

Associations between the Expression of Mucins (MUC1, MUC2, MUC5AC, and MUC6) and Clinicopathologic Parameters of Human Breast Ductal Carcinomas
por: Do, Sung-Im, et al.
Publicado: (2013)

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
por: Fujihara, Miwa, et al.
Publicado: (2021)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Resistance and Overcoming Resistance in Breast Cancer
por: Luque-Bolivar, Andrea, et al.
Publicado: (2020)

Investigating the Relationship Between the Expression Level of Mucin Gene Cluster (MUC2, MUC5A, and MUC5B) and Clinicopathological Characterization of Colorectal Cancer
por: Iranmanesh, Hossein, et al.
Publicado: (2021)

Bacterial Stress Responses as Potential Targets in Overcoming Antibiotic Resistance
por: Dawan, Jirapat, et al.
Publicado: (2022)

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
por: Wang, Zhen-hao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_56pgldecq4qde4jsufp27qthh6